SEC Form 4/A · accession 0001104659-15-003338
Radius Health, Inc. · RDUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owners
Katherine Priestley
10% Owner
F2 Bioscience III, L.P.
10% Owner
F2 Capital Ltd
10% Owner
F2 Bioscience GP Ltd.
10% Owner
Globeways Holdings Ltd
10% Owner
Period of report
Jan 16, 2015
Accepted (ET)
Jan 20, 2015 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001428522
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock WarrantF2,F3,F1 | $14.004 | Jan 16, 2015 | J | 267,786 | D | Apr 23, 2013 | Apr 23, 2018 | Common Stock | 267,786 | 0 | D |
Explanation of responses
- F1The Form 4 filed on January 16, 2015 incorrectly stated the exercise price of the Common Stock Warrant a $2.694. This amendment is being filed to correct the exercise price.
- F2Reflects a liquidating pro rata distribution by the Reporting Person to its limited and general partners.
- F3The reported securities are owned directly by F2 Bioscience III, L.P. ("F2"). F2 Bioscience GP Ltd. ("F2 GP") is the General Partner of F2. Katherine Priestley and Globeways Holdings Limited are members of F2 GP. F2 Capital Limited is an investment adviser to F2. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.